TY - JOUR
T1 - Addressing influenza’s underestimated burden – Iberian experts call to action
AU - Gil-de-Miguel, Ángel
AU - Díez-Domingo, Javier
AU - Martinón-Torres, Federico
AU - Margüello, Esther Redondo
AU - de Lejarazu Leonardo, Raúl Ortiz
AU - Pumarola, Tomàs
AU - de Sousa, Jaime Correia
AU - Rabaçal, Carlos
AU - Raposo, João
AU - Cordeiro, Carlos Robalo
AU - Froes, Filipe
N1 -
Funding Information:
Gil A, Díez-Domingo J, Rabaçal C, Raposo J, Robalo Cordeiro C, have received fees from Sanofi. Martinón Torres F received honoraria from GSK group of companies, Pfizer Inc, Sanofi, MSD, Seqirus, and Janssen for taking part in advisory boards and expert meetings and for acting as a speaker in congresses outside the scope of the submitted work. Martinón Torres F has also acted as principal investigator in randomized controlled trials of the above-mentioned companies as well as Ablynx, Gilead, Regeneron, Roche, Abbott, Novavax, and MedImmune, with honoraria paid to his institution. Martinón Torres F receives support for research activities from the Instituto de Salud Carlos III (Proyecto de Investigación en Salud, Acción Estratégica en Salud): Fondo de Investigación Sanitaria (FIS; PI070069 / PI1000540 / PI1601569 / PI1901090) del plan nacional de I + D + I and FEDER. Ortiz de Lejarazu R received honoraria from AstraZeneca, GSK, MSD, Roche, Sanofi and Seqirus for taking part in advisory boards and expert meetings and for acting as a speaker in congresses outside the scope of the submitted work. Ortiz de Lejarazu R has been until 2019 Director of the National Influenza Centre, Valladolid, Spain without any salary for that position and has participate in regular commitments of Influenza and other respiratory virus surveillance. Pumarola T Received honoraria from Roche, Sanofi, Seegene and Seqirus for taking part in advisory boards and expert meetings and for acting as a speaker in congresses outside the scope of the submitted work. Redondo Margüello E received honoraria from GSK group of companies, Pfizer Inc, Sanofi, and MSD, for taking part in advisory boards and expert meetings and for acting as a speaker in congresses outside the scope of the submitted work. Correia de Sousa J reports Advisory Board from Boehringer Ingelheim; personal fees and Advisory Board from GSK; grants, personal fees, and Advisory Board from AstraZeneca; personal fees and Advisory Board from Bial; non-financial support from Mundipharma; personal fees from Sanofi; Advisory Board from Novartis, outside the submitted work. Froes F reports Advisory Board and personal fees from Sanofi, Pfizer, MSD, Gilead and personal fees or non-financial support from Bial, AstraZeneca, GSK, Novartis, Boehringer Ingelheim, Tecnifar, Lilly, Bayer and Roche outside the submitted work.
Funding Information:
The BARI study was funded by Sanofi. The authors were not paid for writing the publication.
Publisher Copyright:
© 2023, The Author(s).
PY - 2023/5/8
Y1 - 2023/5/8
N2 - Having a proper understanding of the impact of influenza is a fundamental step towards improved preventive action. This paper reviews findings from the Burden of Acute Respiratory Infections study on the burden of influenza in Iberia, and its potential underestimation, and proposes specific measures to lessen influenza’s impact.
AB - Having a proper understanding of the impact of influenza is a fundamental step towards improved preventive action. This paper reviews findings from the Burden of Acute Respiratory Infections study on the burden of influenza in Iberia, and its potential underestimation, and proposes specific measures to lessen influenza’s impact.
KW - Burden
KW - Epidemiology
KW - Hospitalization
KW - Influenza
KW - Portugal
KW - Prevention
KW - Retrospective studies
KW - Spain
KW - Surveillance
KW - Vaccination
UR - http://www.scopus.com/inward/record.url?scp=85158076294&partnerID=8YFLogxK
U2 - 10.1186/s12879-023-08277-x
DO - 10.1186/s12879-023-08277-x
M3 - Comment/debate
AN - SCOPUS:85158076294
SN - 2374-4235
VL - 23
JO - BMC Infectious Diseases
JF - BMC Infectious Diseases
IS - 1
M1 - 308
ER -
